Evidence map›Paper›PMID 36194273›Full record

ReviewParasitology research2022

Recent metabolomic developments for antimalarial drug discovery.

Lúcia Mamede, Fanta Fall, Matthieu Schoumacher, Allison Ledoux, Pascal De Tullio, Joëlle Quetin-Leclercq, Michel Frédérich

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Parasitology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lúcia MamedeLaboratory of Pharmacognosy, Center of Interdisciplinary Research On Medicines (CIRM), University of Liège, CHU B36 Av Hopital 1, B36 4000, Liege, Belgium.
Fanta FallPharmacognosy Research Group, Louvain Drug Research Institute (LDRI), UCLouvain, Avenue E. Mounier B1 72.03, B-1200, Brussels, Belgium.
Matthieu SchoumacherLaboratory of Pharmaceutical Chemistry, Center of Interdisciplinary Research On Medicines (CIRM), University of Liège, Liege, Belgium.
Allison LedouxLaboratory of Pharmacognosy, Center of Interdisciplinary Research On Medicines (CIRM), University of Liège, CHU B36 Av Hopital 1, B36 4000, Liege, Belgium.
Pascal De TullioLaboratory of Pharmaceutical Chemistry, Center of Interdisciplinary Research On Medicines (CIRM), University of Liège, Liege, Belgium.
Joëlle Quetin-LeclercqPharmacognosy Research Group, Louvain Drug Research Institute (LDRI), UCLouvain, Avenue E. Mounier B1 72.03, B-1200, Brussels, Belgium.
Michel FrédérichLaboratory of Pharmacognosy, Center of Interdisciplinary Research On Medicines (CIRM), University of Liège, CHU B36 Av Hopital 1, B36 4000, Liege, Belgium. M.Frederich@uliege.be.
University of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malaria is a parasitic disease that remains a global health issue, responsible for a significant death and morbidity toll. Various factors have impacted the use and delayed the development of antimalarial therapies, such as the associated financial cost and parasitic resistance. In order to discover new drugs and validate parasitic targets, a powerful omics tool, metabolomics, emerged as a reliable approach. However, as a fairly recent method in malaria, new findings are timely and original practices emerge frequently. This review aims to discuss recent research towards the development of new metabolomic methods in the context of uncovering antiplasmodial mechanisms of action in vitro and to point out innovative metabolic pathways that can revitalize the antimalarial pipeline.

Indexed as

AntimalarialsFolic Acid AntagonistsMalariaDrug DiscoveryDrug ResistanceHumansMetabolomicsPlasmodium falciparumAntimalarialsFolic Acid AntagonistsMalariaMass spectrometryMechanism of actionMetabolomicsNuclear magnetic resonancePlasmodium sp.

Identifiers

PMID36194273
OpenAlexW4301392624

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.